Company History

Kraeber & Co was founded on January 1st, 1980. The shareholders are Anja Kuhnert, Franziska Faber, Renate Kraeber, and Kraeber Verwaltung GmbH, Rellingen, Germany.

Kraeber is producer of active pharmaceutical ingredients (API) and excipients for the pharmaceutical, biotechnological, diagnostic, cosmetic, health food, and the food and feed industries.

1980 Start of activities, production of various organic chemicals in co-operation with medium sized and small sub-contractors and laboratories. Sale of Heparin Sodium from South-America on an agency basis.
1982 Production of standardized sheep plasma for the determination of the activity of Heparin.
1984 Kraeber Arzneirohstoff GmbH, Halstenbek, was founded for production of animal blood fractions from locally reared animals.
1986 Purification of crude Heparin to Heparin salts of high purity.
1990 Exclusive marketing and sales contracts with various well known companies for biochemicals.
1993 Purchase of the production facilitiy from BIOSPA Wedel. Merger with Kraeber Arzneirohstoff GmbH, Halstenbek. Kraeber advances to be the largest manufacturer of animal blood fractions in Europe.
1996 Kraeber (UK) Ltd. was established for the sale of our products in the UK and the development of formulations for nutraceuticals, animal care and animal feed products.
1998 Purchase of a 4.000 m² area site in Ellerbek near Hamburg, including a 1.200 m² production and storage hall and a 740 m² office building.
1998 A substantial number of active enzymes, hormones, proteins, carbon hydrates as well as porphyrines have been added to the list of products. Our Division "Biochemical Substances" is growing rapidly.
1999 The production laboratory, built "state of the art" as per GMP rules started the blood fractionation reared from 18 species, and the production of other biologicals.
2001 Kraeber installed the 'CHARISMA' software of the GUS AG, Köln. The software has been validated according to GMP.
2002 Jan Michael Kraeber becomes Managing Director and 50% Shareholder. We started to transfer the management to the next generation.
2002 We extended the space of production and offices by 150 m² each.
2005 We installed a 44,5 kWp Photovoltaic system. Our active contribution to protect the environment.
2008 We extended our production facilities in compliance with GMP.
2009 Change of legal form. Kraeber GmbH & Co KG has been changed to Kraeber & Co GmbH.
2010 Caused by the death of Shareholder and Managing Director Jan-Michael Kraeber the company had to be restructured. Shareholders and Managing Directors are now:
Jens-Uwe Kraeber, Anja Kuhnert, and Franziska Faber.
2012 GMP Compliance
Our facilities have been inspected in accordance with art.111(5) of directive 2001/83/EC in connection with manufacturing authorisation DE_SH_01_MIA_112_0008/113.14 in accordance with art.40 of directive 2001/83/EC transposed in the following national legislation sect.13 para.1 AMG (German Drug Law) and is an active substance manufacturer that has been inspected in accordance with art.111(1) of directive 2001/83/EC transposed in the following national legislation sect.84 para.1 AMG (German Drug Law).
From the knowledge gained during the inspection of this manufacturer, the latest of which was conducted on 24/11/2011, it is considered that it complies with the Good Manufacturing Practice requirements for active substances referred to in art.47 of directive 2001/83/EC.
Top of Page
Please inform our about problems with this page.
Design & Service by InWise® GmbH, D-25474 Ellerbek
Last modified on May, 24. 2018.